Annual Report FY 2025-26 submitted to BSE

Revenue growth above 20%Profit growth above 25%Results View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.3%Reaction day

₹146.60

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%+3.7% vs market

Pharmaceuticals peers, median of 174sector-0.1%+4.4% vs sector

On the reaction day the stock moved 3.7 pts more than Nifty Microcap 250 and 4.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.3+0.7+3.7-0.1+4.4

Next day

+3.8+1.1+2.7+0.1+3.7

+4.9+1.6+3.3+0.8+4.2

+5.6+1.5+4.2+0.1+5.5

+7.8+1.3+6.5+0.6+7.2

+13.9+1.4+12.5-0.1+14.0

+5.7-2.1+7.7-1.6+7.3

15d

+12.5-0.9+13.4-1.0+13.5

—-1.4—-2.8—

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Speciality Medicines submitted its FY25-26 Annual Report to BSE. Revenue from operations rose to Rs 7,528.51 lakh from Rs 5,827.14 lakh, up about 29 percent year on year. Net profit jumped to Rs 1,303.29 lakh from Rs 719.62 lakh, nearly 81 percent higher. The company listed on the BSE SME platform on March 30, 2026 after a successful IPO that raised Rs 2,914 lakh at Rs 124 per share. No dividend declared as profits are being retained for expansion.

Likely market impact

Strong revenue and profit growth in first listed year, signals healthy business momentum for shareholders.